Taken together, we show that high affinity CD19 CAR T cells confer substantial antigen loss in many of the major tumor types currently approved or under clinical investigation for treatment with high affinity CD19 CAR T cells, potentially fueling a reservoir of persistent antigen-negative tumor cells. This evidence concerns the gene CD19 and neoplasm.